Hepatitis C virus (HCV) non-structural protein 5B (NS5B), which is being studied for its RNA-dependent RNA polymerase (RDRP). It has been demonstrated that the RDRP is highly mobile and that it is crucial for viral replication. NS5B protein inhibition, which restricts viral RNA polymerase activity, is how sofosbuvir (SFV) stops viral replication. All first-line treatments for HCV genotypes 1-6 and a few second-line treatments need the use of sofosbuvir in conjunction with additional medications. For genotypes with a fixed speed of more than 90%, and typically around 100%, the combination of SFV and VLE is successful and advised. Infected patients with the human immunodeficiency virus (HIV) use it to increase endurance and prevent forced contaminations. This research offers a concurrent and comparative evaluation of the analytical studies reported in the literature for pharmacological estimation as a look ahead. More than 150 papers from eminent institutions doing scientific, technological, and medical research are currently available. A thorough description of the conventional, hyphenated, and distinctive SFV approaches has been successfully presented in the current review. Additionally, new NS5B inhibitor SFV has been considered to have therapeutic promise along with cutting-edge analytical research.
Rangari, Shyam W. and Bari, Sanjaykumar B.
"Analytical Profiling of Sofosbuvir as NS5B Protein Inhibitor for Oral Drug Delivery: Method development and Validation,"
Bulletin of Faculty of Pharmacy Cairo University: Vol. 60
, Article 4.
Available at: https://doi.org/https://doi.org/10.54634/2090-9101.1036
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.